UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

 

(Amendment No. 1)*

Imprimis Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, $0.001 par value

(Title of Class of Securities)

45323A201

(CUSIP Number)

March 21, 2017

(Date of Event which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

[_] Rule 13d-1(b)

 

X   Rule 13d-1(c)

 

[_] Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

SCHEDULE 13G

 

CUSIP No.

45323A201

 

1	Names of Reporting Persons
	Longboard Capital Advisors, LLC (EIN 86-1150459)   Brett Conrad
2	Check the appropriate box if a member of a Group (see instructions)
	(a)  [  ] (b)  [  ]
3	SEC Use Only
4	Citizenship or Place of Organization
	Longboard Capital Advisors, LLC – Delaware   Brett Conrad – USA
Number of Shares Beneficially Owned by Each Reporting Person With:		5	Sole Voting Power
			1,416,000 aggregate shares of Common Stock (see Item 4 below)
		6	Shared Voting Power
			0
		7	Sole Dispositive Power
			1,416,000 aggregate shares of Common Stock (see Item 4 below)
		8	Shared Dispositive Power
			0
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	1,416,000 aggregate shares of Common Stock (see Item 4 below)
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	[  ]
11	Percent of class represented by amount in row (9)
	7.1%

12	Type of Reporting Person (See Instructions)
	Longboard Capital Advisors, LLC – IA   Brett Conrad – IN

 

Item 1.

 

(a)	Name of Issuer
	Imprimis Pharmaceuticals, Inc.
(b)	Address of Issuer’s Principal Executive Offices
	12264 El Camino Real, Suite 350
	San Diego, CA 92130

Item 2.

 

(a)	Name of Person Filing
	Longboard Capital Advisors, LLC
	Brett Conrad
(b)	Address of Principal Business Office or, if None, Residence
	1312 Cedar St. Santa Monica, California 90405
(c)	Citizenship
	Longboard Capital Advisors, LLC – Delaware
	Brett Conrad – USA
(d)	Title and Class of Securities
	Common Stock, $0.001 par value
(e)	CUSIP No.
	45323A201

 

Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

	(a)	[_]	Broker or dealer registered under Section 15 of the Act;
	(b)	[_]	Bank as defined in Section 3(a)(6) of the Act;
	(c)	[_]	Insurance company as defined in Section 3(a)(19) of the Act;
	(d)	[_]	Investment company registered under Section 8 of the Investment Company Act of 1940;
	(e)	[_]	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
	(f)	[_]	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
	(g)	[_]	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
	(h)	[_]	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
	(i)	[_]	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
	(j)	[_]	A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
	(k)	[_]	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

 

Item 4.	Ownership
(a)	Amount Beneficially Owned: 1,416,000 aggregate shares of Common Stock may be deemed to be beneficially owned by the Reporting Person, which includes 208,000 shares of Common Stock issuable upon exercise of Warrants.
(b)	Percent of Class: 7.1%
(c)	Number of shares as to which such person has:

	(i)	Sole power to vote or to direct the vote: 1,416,000 aggregate shares of Common Stock (See Item 4a above).
	(ii)	Shared power to vote or to direct the vote: 0
	(iii)	Sole power to dispose or to direct the disposition of: 1,416,000 aggregate shares of Common Stock (See Item 4a above).
	(iv)	Shared power to dispose or to direct the disposition of: 0

Item 5.	Ownership of Five Percent or Less of a Class.
	If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
Item 6.	Ownership of more than Five Percent on Behalf of Another Person.
	This Item 6 is not applicable.
Item 7.	Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.
	This Item 7 is not applicable.
Item 8.	Identification and classification of members of the group.
	This Item 8 is not applicable.
Item 9.	Notice of Dissolution of Group.
	This Item 9 is not applicable.
Item 10.	Certifications.
	By signing below the Reporting Person certifies that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: April 19, 2017

 

/s/ Brett Conrad

 

Name: Brett Conrad

 

Title: Managing Member

 

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

 

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).